How Long Does It Take to Quality Check a Case Before Submission?

In the field of pharmacovigilance, ensuring the safety of pharmaceutical products is paramount. One of the most critical steps in this process is the quality check (QC) of adverse event (AE) cases before submission to regulatory authorities. This step is crucial not only for regulatory compliance but also for safeguarding patient safety and maintaining the integrity of the pharmacovigilance system. But the question often arises: how long does it take to quality check a case before submission?

The answer is not straightforward. The duration depends on multiple factors, including the complexity of the case, the source of the report, the quality of the initial data, the experience of the quality reviewer, and the tools or systems being used for case management. Understanding these factors is essential for organizations looking to optimize their pharmacovigilance operations.

Understanding the Quality Check Process in Pharmacovigilance

A quality check in pharmacovigilance typically involves reviewing an Individual Case Safety Report (ICSR) for completeness, accuracy, and compliance with regulatory requirements. ICSRs can come from multiple sources, such as healthcare professionals, patients, clinical trials, literature reports, or spontaneous reporting systems. Each case must be evaluated carefully to ensure that critical information is captured, including patient demographics, drug information, adverse events, outcomes, and reporter details.

The quality check process usually includes:

1. Verification of Case Completeness: Ensuring that all mandatory fields are filled, such as patient age, sex, medical history, concomitant medications, and detailed descriptions of the adverse event. Missing information can lead to delays or queries from regulatory authorities.

2. Accuracy and Consistency Checks: Cross-verifying the information for consistency, such as checking that the drug administration dates align with the onset of adverse events, and confirming that medical terminology is used correctly.

3. Coding and Classification: Assigning appropriate medical codes to adverse events using standardized terminologies like MedDRA (Medical Dictionary for Regulatory Activities) and ensuring drugs are coded according to WHO Drug Dictionary standards. Accurate coding is essential for signal detection and regulatory reporting.

4. Causality Assessment: Reviewing the relationship between the drug and the adverse event. This assessment may involve analyzing the temporal relationship, alternative causes, and previous knowledge of the drug’s safety profile.

5. Regulatory Compliance Check: Ensuring that the report meets the regulatory requirements of the region where it will be submitted. This may include compliance with FDA, EMA, or local regulatory authority guidelines.

6. Final Review and Approval: Once the case passes all checks, it is approved for submission to the relevant regulatory authority, such as the FDA Adverse Event Reporting System (FAERS) or EudraVigilance in Europe.

   
   

Factors Affecting QC Duration

Several factors can influence how long it takes to complete a quality check. Understanding these factors can help organizations streamline their processes and reduce submission delays.

1. Complexity of the Case: Simple cases involving one drug and one adverse event may take as little as 30 to 60 minutes for QC. In contrast, complex cases with multiple drugs, comorbidities, and serious adverse events can take several hours. Clinical trial cases or literature cases often require extensive literature review, medical assessment, and cross-verification, extending the QC time significantly.

   
   

2. Quality of Initial Data: If the initial case report is complete and accurate, the QC process is faster. However, incomplete reports, unclear medical histories, or missing lab data require additional investigation, increasing the QC time. Sometimes, follow-up with the reporter is needed to clarify details, which can add days to the process.

   
   

3. Experience and Expertise of Reviewers: Experienced pharmacovigilance professionals can quickly identify errors, inconsistencies, and compliance issues, reducing QC time. In contrast, less experienced reviewers may require more time to navigate complex cases, consult medical references, or seek guidance from senior staff.

   
   

4. Volume of Cases: High-volume reporting periods can slow down QC if there are insufficient resources. Organizations need to balance workload, staff availability, and timelines to ensure timely and accurate submissions.

   
   

5. Tools and Technology: Advanced pharmacovigilance case management systems, automated coding tools, and AI-powered review platforms can significantly reduce QC time. Manual processes are slower and prone to human error, whereas automated systems help streamline case review, detect discrepancies, and ensure regulatory compliance efficiently.

   
   

Typical QC Timelines

While timelines vary, industry standards and benchmarks suggest the following general ranges:

• Simple spontaneous cases: 30–60 minutes per case

• Serious adverse events or complex cases: 2–4 hours per case

• Cases requiring follow-up or additional information: Several days, depending on the responsiveness of the reporter and the complexity of the data

It is important to note that these timelines are indicative. Organizations may have their internal SOPs defining maximum turnaround times for QC to ensure timely submission while maintaining high-quality standards. Regulatory authorities also expect prompt reporting of serious cases, often within 15 calendar days of receiving the information, making efficiency crucial.

Challenges in the QC Process

The QC process, though critical, is not without challenges:

1. Incomplete or Poor-Quality Data: Reports often come with missing information, vague descriptions, or inconsistent medical terms. This requires follow-up and delays QC.

2. Complex Case Scenarios: Polypharmacy cases, drug interactions, and adverse events with multiple possible causes complicate causality assessments.

3. Regulatory Variations: Different regions may have varying submission requirements, leading to additional steps for compliance.

4. Manual Processes: Reliance on manual review increases the risk of errors and inconsistencies, which can affect case quality and regulatory compliance.

5. High Volume of Reports: During product launches or safety alerts, the influx of reports can overwhelm QC teams, leading to backlogs and delayed submissions.

   
   

How Tesserblu Can Help Streamline QC in Pharmacovigilance

Tesserblu offers specialized solutions designed to optimize pharmacovigilance operations, including the quality check process. By leveraging advanced technology and automation, Tesserblu helps reduce the time required for QC while improving accuracy and compliance. Here’s how:

1. Automated Case Triage and Prioritization: Tesserblu’s platform can automatically categorize cases based on seriousness, complexity, and regulatory deadlines. This ensures that high-priority cases are reviewed first, minimizing the risk of delayed submissions.

   
   

2. AI-Powered Data Validation: Tesserblu uses AI to identify missing or inconsistent information in case reports, suggest corrections, and flag potential errors. This reduces manual effort and ensures that all necessary data is captured accurately.

   
   

3. Standardized Coding and Terminology: The platform integrates automated MedDRA and WHO Drug Dictionary coding, ensuring consistency and compliance across all cases. Accurate coding accelerates signal detection and simplifies regulatory reporting.

   
   

4. Workflow Automation: Tesserblu allows QC teams to establish standardized workflows, including automated alerts, reminders, and follow-up tasks. This ensures that no step is missed and reduces the risk of human error.

   
   

5. Analytics and Reporting: The platform provides real-time insights into QC metrics, such as average review time, error rates, and case backlog. These analytics help organizations identify bottlenecks, optimize resource allocation, and improve overall efficiency.

   
   

6. Regulatory Compliance Assurance: Tesserblu keeps teams up-to-date with evolving regulatory requirements, ensuring that all submissions meet global standards. This reduces the risk of non-compliance, regulatory queries, or penalties.

   
   

By implementing Tesserblu, organizations can transform the QC process from a time-consuming, manual task into a streamlined, efficient, and accurate workflow. Teams can focus on complex case assessments rather than spending hours on repetitive tasks, ultimately improving patient safety and regulatory adherence.

Conclusion

The time it takes to quality check a case before submission in pharmacovigilance varies significantly based on case complexity, data quality, reviewer expertise, and the tools used. While simple cases may take less than an hour, complex cases can take several hours or even days, especially when follow-up with reporters is needed.

Despite these challenges, effective QC is non-negotiable in pharmacovigilance. Accurate, complete, and timely reporting ensures regulatory compliance, protects patients, and supports the broader goal of drug safety monitoring.

Solutions like Tesserblu play a pivotal role in optimizing the QC process. By leveraging automation, AI-driven data validation, and workflow management, Tesserblu helps organizations reduce QC time, improve accuracy, and maintain compliance. In an industry where time and precision are critical, adopting such advanced tools can make a substantial difference in operational efficiency and overall pharmacovigilance quality. Book a meeting if you are interested to discuss more.